Search

Displaying results 4051 - 4060 of 7284 in total
  1. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Defibrotide

    go.drugbank.com/drugs/DB04932
    ApprovedInvestigational

    Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. … It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.

  3. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib has a monoisotopic molecular weight of 494.2 Da. … Tizaterkib is a small molecule drug. The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor.

  4. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat has a monoisotopic molecular weight of 494.21 Da. … Mizacorat is a small molecule drug. The usage of the INN stem '-corat' in the name indicates that Mizacorat is a glucocorticoid receptor agonist.

  5. Drug

    Monlunabant

    go.drugbank.com/drugs/DB21537
    Investigational

    Monlunabant has a monoisotopic molecular weight of 590.11 Da. … Monlunabant is a small molecule drug. The usage of the INN stem '-nabant' in the name indicates that Monlunabant is a cannabinoid receptor antagonist.

  6. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  7. Target

    Proteasome subunit beta type-1

    go.drugbank.com/bio_entities/BE0002347
    TargetHumans

    Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)

    Synonyms: Multicatalytic endopeptidase complex subunit C5
  8. Drug

    Difenoxin

    go.drugbank.com/drugs/DB01501
    ApprovedIllicit

    Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. … Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea.

  9. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

  10. Drug

    Cortisone acetate

    go.drugbank.com/drugs/DB01380
    ApprovedInvestigational

    [A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107] … [A226295] Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory